http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113816976-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f38f155c00d753dbe3842a78b12d66f6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 |
| filingDate | 2021-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc65e98d26134efb775b72c1151f7b42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a4da39a443ecbe3aee876bd4c123d84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_271449af37dc10355c8a5015a0ca829d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5358907b266eccaeb15fe723d39fcaec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a6379ca30c6a1428845d07063abf1b4 |
| publicationDate | 2021-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113816976-A |
| titleOfInvention | Isochrysine analogue prepared from moxifloxacin as raw material and preparation method and application thereof |
| abstract | The invention discloses an isoalburnine analogue, a preparation method and application thereof, wherein the chemical structure of the isoalburnine analogue is shown as the following formula I: the substituent R in the formula I can be independently-H-OCH or-OCH 3 -F, -Cl or-SO 2 NH 2 . The isoleucinine analogue takes moxifloxacin as a raw material, realizes effective chemical construction from a fluoroquinolone structure to an indoloquinoline skeleton, expands a new way of structural modification of isoleucinine, achieves the complementation of the advantageous structures of fluoroquinolone medicines and natural indoloquinoline alkaloids, further increases the anti-tubercle bacillus activity and the anti-drug resistance of the compound, and reduces the drug resistance of the compoundThe toxicity to normal cells can be further developed as an antitubercular drug with a brand-new structure. |
| priorityDate | 2021-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 83.